CORRESP Filing
TuHURA Biosciences, Inc./NV
Date: Sept. 24, 2025 · CIK: 0001498382 · Accession: 0001193125-25-215424
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289532
Letter
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS TuHURA Biosciences, Inc. Registration Statement on Form S-1 File No. 333-289532 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Friday, September 26, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. Thank you for your assistance. The Registrant respectfully requests that you notify Curt Creely of Foley & Lardner LLC of such effectiveness by a telephone call to (813) 225-4122.
TUHURA BIOSCIENCES, INC. 10500 University Center Drive, Suite 110 Tampa, FL 33612 September 24, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549
Very truly yours,
TUHURA BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP TUHURA BIOSCIENCES, INC. 10500 University Center Drive, Suite 110 Tampa, FL 33612 September 24, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS TuHURA Biosciences, Inc. Registration Statement on Form S-1 File No. 333-289532 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Friday, September 26, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. Thank you for your assistance. The Registrant respectfully requests that you notify Curt Creely of Foley & Lardner LLC of such effectiveness by a telephone call to (813) 225-4122. Very truly yours, TUHURA BIOSCIENCES, INC. By: /s/ James Bianco Name: James A. Bianco, M.D. Title: Chief Executive Officer